Condition: Kawasaki Disease · Coronary Artery Aneurysm · Rivaroxaban · Sponsor: Children's Hospital of Fudan University
Based on an established Kawasaki disease cohort database, this prospective, single-center, single-arm, observational study will collect clinical data from children aged 2 years and older with giant coronary artery aneurysms after Kawasaki disease who received rivaroxaban treatment. Rivaroxaban plasma concentrations, anti-factor Xa activity levels, and genetic polymorphisms will be measured and analyzed to support the population pharmacokinetic/pharmacodynamic analysis
This description comes directly from the study's public registry record.
Fang Liu, MD · 18017590880 · liufang@fudan.edu.cn
Guangan Dai, MD · 13580762996 · gadai24@m.fudan.edu.cn
Always discuss trial participation with your own doctor first.
| Children's Hospital of Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06993636